News
-
-
PRESS RELEASE
BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study
BioNxt Solutions Inc. announces the advancement of its sublingual Everolimus oral dissolvable film program targeting organ transplantation, with a comparative pharmacokinetic study -
-
PRESS RELEASE
BioNxt Advances Cladribine Clinical Program for MS with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies
BioNxt Solutions Inc. announces completion of the Investigational Medicinal Product Dossier (IMPD) for BNT23001, their proprietary sublingual cladribine oral dissolvable film product for multiple sclerosis. Key regulatory milestone achieved -
-
-
-
PRESS RELEASE
BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies
BioNxt Solutions Inc. completes Investigational Medicinal Product Dossier (IMPD) for BNT23001, a sublingual cladribine oral dissolvable film for multiple sclerosis. IMPD is a significant regulatory milestone for the Company's lead drug candidate -
-
PRESS RELEASE
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
BioNxt Solutions Inc. provides update on proprietary sublingual thin-film drug delivery pipeline including Cladribine for multiple sclerosis, autoimmune disease expansion, Everolimus, and Semaglutide
